Skip to content

US · CTOR · DRUG MANUFACTURERS - GENERAL

Citius Oncology, Inc. (CTOR) intrinsic value and stock valuation

$0.50as of 2026-11-21 · Mkt cap 70.01M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Citius Oncology, Inc. DCF and intrinsic value

InvestorsCraft values CTOR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CTOR’s statements →

Citius Oncology, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - General Cranford, NY 07016 citiusonc.com

How the business is doing

Fiscal 2022–2025, USD

Revenue
$0.00
20222025
Net income
-$-24.76M
20222025
Free cash flow
-$-5.49M
20222025
Total equity
$44.9M
20222025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2022–2025, USD
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Operating income-$-23.52M-$-20.57M-$-12.12M-$-9.71M
Net income-$-24.76M-$-21.15M-$-12.7M-$-10.87M
EPSd-$-337.93K-$-295.6K-$-141.93K-$-120.56K
Operating cash flow-$-5.49M$130K-$-600K-$-50K
Capital expenditure-$0.00-$0.00$0.00$0.00
Free cash flow-$-5.49M$130K-$-600K-$-50K
Total assets$100.9M$84.4M$47.7M$42.7M
Total debt$3.8M$3.8M$0.00$0.00
Net debt-$-120K$3.8M$0.00$0.00
Total equity$44.9M$46.1M$25.5M$36.3M
Cash and short-term investments$3.92M$0.00$0.00$0.00
Income statement
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00
Research and development expenses$6.42M$4.92M$4.24M$6.86M
Selling, general and administrative expenses$17.1M$15.7M$7.88M$2.86M
Other expenses$0.00$0.00$0.00$0.00
Operating expenses$23.5M$20.6M$12.1M$9.71M
Cost and expenses$23.5M$20.6M$12.1M$9.71M
Interest income$40K$0.00$0.00$0.00
Interest expense$220K$0.00$0.00$0.00
Depreciation and amortization$0.00$0.00$0.00$9.71M
Ebitda-$-23.49M-$-20.57M-$-12.12M$0.00
Operating income-$-23.52M-$-20.57M-$-12.12M-$-9.71M
Total other income/expenses, net-$-180K$0.00$0.00$0.00
Income before tax-$-23.7M-$-20.57M-$-12.12M-$-9.71M
Income tax expense$1.06M$580K$580K$1.15M
Net income-$-24.76M-$-21.15M-$-12.7M-$-10.87M
Weighted average shares outstanding$73.3M$71.6M$89.5M$90.2M
Weighted average diluted shares outstanding$73.3M$71.6M$89.5M$90.2M
Balance sheet
2025202420232022
Cash and short-term investments$3.92M$0.00$0.00$0.00
Net receivables$0.00$0.00$0.00$0.00
Inventory$22.3M$8.27M$0.00$0.00
Total current assets$27.5M$11M$7.73M$2.69M
Property, plant and equipment, net$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00
Total non-current assets$73.4M$73.4M$40M$40M
Total assets$100.9M$84.4M$47.7M$42.7M
Accounts payable$13.2M$3.71M$1.29M$90K
Short-term debt$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00
Total current liabilities$49.5M$32.7M$21.1M$5.85M
Long-term debt$3.8M$3.8M$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00
Total non-current liabilities$6.59M$5.53M$1.15M$580K
Capital lease obligations$0.00$0.00$0.00$0.00
Total liabilities$56.1M$38.2M$22.2M$6.42M
Common stock$10K$10K$10K$10K
Retained earnings-$-64.04M-$-39.28M-$-18.13M-$-5.43M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00
Total equity$44.9M$46.1M$25.5M$36.3M
Total investments$0.00$0.00$0.00$0.00
Total debt$3.8M$3.8M$0.00$0.00
Net debt-$-120K$3.8M$0.00$0.00
Cash flow statement
2025202420232022
Net income-$-24.76M-$-21.15M$2.42M$380K
Depreciation and amortization$0.00$0.00$0.00$0.00
Stock-based compensation$0.00$0.00$0.00$0.00
Change in working capital$9.89M$13.2M$410K$60K
Accounts receivable$0.00$0.00$350K$30K
Inventory-$-12.65M-$-2.13M$0.00$0.00
Accounts payable$9.52M$2.42M$0.00$0.00
Net cash provided by operating activities-$-5.49M$130K-$-600K-$-50K
Investments in property, plant and equipment$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-5.75M-$-5M-$-1.32M-$-67.32M
Common stock issued$15.2M$0.00$0.00$68M
Common stock repurchased$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00
Net cash used for financing activities$15.2M$4.87M$1.66M$67.7M
Net change in cash$3.92M-$-30K-$-260K$290K
Cash at end of period$3.92M$0.00$30K$290K
Operating cash flow-$-5.49M$130K-$-600K-$-50K
Capital expenditure-$0.00-$0.00$0.00$0.00
Free cash flow-$-5.49M$130K-$-600K-$-50K
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Citius Oncology, Inc.

        Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.

        CEO
        Leonard L. Mazur
        Employees
        285
        Beta
        3.48

        Explore

        Frequently asked questions

        What is the intrinsic value of Citius Oncology, Inc. (CTOR)?

        InvestorsCraft does not currently publish an intrinsic value for CTOR. How the IC value is calculated.

        Is CTOR undervalued?

        InvestorsCraft does not publish an undervaluation signal for CTOR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.